Scarica l'app Stockscreener
6.96
4.26%
-0.31
Dopo l'orario di chiusura:
6.96
Precision Biosciences Inc Borsa (DTIL) Ultime notizie
Precision BioSciences stock (US74019P1084): gene-editing player updates clinical pipeline and strate - AD HOC NEWS
Number of shareholders of Precision BioSciences, Inc. – NASDAQ:DTIL - TradingView
DTIL Stock Chart | PRECISION BIOSCIENCES INC (NASDAQ:DTIL) - ChartMill
Precision BioSciences (DTIL) Highlights Promising Data in DMD Tr - GuruFocus
Precision Biosciences Presents New Preclinical Data Supporting Advancement of Pbgene-Dmd into Clinic - marketscreener.com
Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Cl - PharmiWeb.com
Precision BioSciences (DTIL) Highlights Promising Data in DMD Treatment - GuruFocus
Precision BioSciences presents DMD gene therapy preclinical data - Investing.com
Precision BioSciences presents DMD gene therapy preclinical data By Investing.com - Investing.com Canada
Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting - Business Wire
Analyst Forecasts For Precision BioSciences, Inc. (NASDAQ:DTIL) Are Surging Higher - simplywall.st
Bullish: Analysts Just Made A Notable Upgrade To Their Precision BioSciences, Inc. (NASDAQ:DTIL) Forecasts - Yahoo Finance
Precision BioSciences stock (US74019P1084): Q3 2024 earnings report shows EPS loss - AD HOC NEWS
Precision BioSciences exits substantial shareholder role in Imugene - TipRanks
DTIL SEC FilingsPrecision Biosciences 10-K, 10-Q, 8-K Forms - Stock Titan
Precision BioSciences (DTIL) reports Q1 loss, tops revenue estimates - MSN
Analysts’ Top Healthcare Picks: Precision BioSciences (DTIL), Nuvectis Pharma (NVCT) - The Globe and Mail
Guggenheim Initiates Precision BioSciences(DTIL.US) With Buy Rating, Announces Target Price $19 - Moomoo
H.C. Wainwright Maintains Precision BioSciences(DTIL.US) With Buy Rating, Maintains Target Price $60 - Moomoo
Precision BioSciences Q1 2026 earnings preview - MSN
Precision BioSciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
MSN Money - MSN
DTIL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Precision BioSciences reports Q1 EPS (75c) vs. ($2.21) last year - TipRanks
Precision BioSciences (DTIL) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Precision BioSciences (DTIL) Q1 2026 loss narrows as gene-editing pipeline advances - Stock Titan
Precision BioSciences 1Q 2026: Revenue $10.8M, EPS $(0.75) — 10-Q Summary - TradingView
Precision BioSciences (DTIL) posts Q1 2026 results and advances HBV and DMD gene editing - Stock Titan
DTIL: Advanced gene editing trials and improved financials, with strong cash runway through 2028 - TradingView
Precision BioSciences: Q1 Earnings Snapshot - marketscreener.com
BRIEF-Precision BioSciences, Inc. Q1 Revenue USD 10.838 Million Vs. IBES Estimate USD 4.05 Million - TradingView
Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update - Yahoo Finance
Precision BioSciences (DTIL) Set to Report Q1 2026 Earnings with Analyst Expectations - GuruFocus
Precision BioSciences (DTIL) Projected to Post Earnings on Tuesday - MarketBeat
Precision BioSciences Inc expected to post a loss of 65 cents a shareEarnings Preview - TradingView
Precision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026 - BioSpace
Press Release: Precision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026 - Moomoo
H.C. Wainwright Reaffirms Their Buy Rating on Precision BioSciences (DTIL) - The Globe and Mail
Precision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study - BioSpace
Precision BioSciences (DTIL) Launches First Clinical Trial for P - GuruFocus
Precision BioSciences opens enrollment for DMD gene therapy trial By Investing.com - Investing.com South Africa
Precision BioSciences opens enrollment for DMD gene therapy trial - Investing.com
2.53%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):